Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Down 14.8% in December

Aprea Therapeutics, Inc. (NASDAQ:APRE) saw a large decline in short interest in December. As of December 31st, there was short interest totalling 10,900 shares, a decline of 14.8% from the December 15th total of 12,800 shares. Based on an average daily volume of 28,500 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.2% of the shares of the company are short sold.

Aprea Therapeutics Price Performance

APRE traded down $0.04 during trading on Thursday, reaching $3.63. 2,389 shares of the stock were exchanged, compared to its average volume of 42,959. The company has a market capitalization of $19.71 million, a price-to-earnings ratio of -1.29 and a beta of 0.75. Aprea Therapeutics has a 1 year low of $2.15 and a 1 year high of $8.85. The business’s 50 day moving average price is $3.35 and its two-hundred day moving average price is $3.46.

Aprea Therapeutics (NASDAQ:APRE) last posted its earnings results on Thursday, November 7th. The company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.11. The firm had revenue of $0.35 million during the quarter, compared to the consensus estimate of $0.45 million. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%. On average, analysts anticipate that Aprea Therapeutics will post -2.55 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Aprea Therapeutics in a research note on Wednesday.

Insider Buying and Selling at Aprea Therapeutics

In other Aprea Therapeutics news, Director Marc Duey sold 6,462 shares of the firm’s stock in a transaction on Friday, October 18th. The stock was sold at an average price of $4.58, for a total value of $29,595.96. Following the completion of the sale, the director now owns 233,651 shares of the company’s stock, valued at approximately $1,070,121.58. This trade represents a 2.69 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 12.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. Dimensional Fund Advisors LP purchased a new position in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned about 0.20% of Aprea Therapeutics as of its most recent SEC filing. 34.19% of the stock is owned by institutional investors.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.